• Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharmaceuticals

ALKS:US

48.7100 USD 0.7700 1.61%

As of 20:10:00 ET on 07/09/2014.

Snapshot for Alkermes PLC (ALKS)

Open: 48.4700 Day's Range: 46.7700 - 48.8500 Volume: 655,521
Previous Close: 47.9400 52wk Range: 28.6800 - 54.2500 1-Yr Rtn: +64.39%

Stock Chart for ALKS

No chart data available.
  • ALKS:US 48.6700
  • 1D
  • 1M
  • 1Y
47.9400
Interactive ALKS Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ALKS

Current P/E Ratio (ttm) 928.1100
Estimated P/E(12/2014) 95.8858
Relative P/E vs. SPX 51.3685
Earnings Per Share (USD) (ttm) 0.0525
Est. EPS (USD) (12/2014) 0.5080
Est. PEG Ratio 4.1509
Market Cap (M USD) 7,039.33
Shares Outstanding (M) 144.52
30 Day Average Volume 723,765
Price/Book (mrq) 5.2526
Price/Sale (ttm) 11.9047
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 07/25/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ALKS

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for ALKS

Alkermes PLC researches pharmaceuticals. The Company develops treatments for central nervous system disorders such as addiction, schizophrenia and depression, and diabetes.

Richard F PopsChairman/CEOShane CookePresident
James M Frates "Jim"Senior VP/CFO/TreasurerGordon G PughSenior VP/COO/Chief Risk Ofcr
More Company Profile & Key Executives for ALKS

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil